The activation of the MAPK and PI3K pathways is nearly universal in melanoma tumors principally due to mutually exclusive mutations in BRAF (40–50% of cases) or NRAS (15–20%) or to the losses of NF1 expression (13%) that may co-occur with BRAF or NRAS mutations [30,31]. This evidence concerns the gene NRAS and melanoma.